#118097
Re: Farmas USA
Acasti Pharma – On The Cusp Of Greatness
Summary
A relatively unknown biotech north of the border – ACST – has been working for the past five years on a miracle drug called "CaPre" as a treatment for CVD.
The key Phase “Trilogy 1 & 2” trial results for CaPre are due out any day now with T1 data promised by Christmas and T2 following in early January 2020.
Market leading provider of Omega-3 (OM-3) treatments - AMRN through its fish oil-derived "Vascepa" - has achieved a market cap of $8BN as it blazed a path in the USA.
ACST's product derived from krill oil has numerous potential benefits and applications above and beyond Vascepa that could push its own valuation far beyond the path achieved by AMRN targeting CVD alone.
It appears that smart money including well known biotech investors and funds have been loading up on ACST this year as evidenced by institutional/insider % ownership more than doubling from around 14% earlier in 2019 to 30%+ as per recent reports. Further catalysts aside from T2 are the release of secondary and exploratory endpoints in March 2020, presentation of the full dataset at “important” scientific meetings and, most importantly, the filing of a new drug application to obtain FDA approval for release into the U.S. market. With T1 P3 data to be delivered imminently (read - today/Monday) and its likelihood to prove CaPre as “best of breed”, .............
we initiate ACST with a STRONG BUY recommendation and a price target of $10, which represents an enterprise value (EV) of roughly $1BN.
-- "CaPre" based on krill oil, which has potential additional benefits and wider application than Vascepa.
-- Importantly, CaPre could be a complementary potential treatment for diabetes which is a vast market Vascepa and other OM-3 drugs do not address.
https://seekingalpha.com/instablog/50093457-best-on-the-street/5388255-acasti-pharma-on-cusp-of-greatness
